ALGS Aligos Therapeutics Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Woiwode Thomas	2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ ALGS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 4/26/2021
(Street) SOUTH SAN FRANCISCO, CA 94080 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	4/26/2021		J(1)		485979	D	$0.00	1943916	I	See Footnote (2)
Common Stock	4/26/2021		J(3)		9720	A	$0.00	9720	I	See Footnote (4)
Common Stock	4/26/2021		J(5)		9720	D	$0.00	0	I	See Footnote (4)
Common Stock	4/26/2021		J(6)		8385	A	$0.00	8385	I	See Footnote (7)
Common Stock	4/26/2021		J(8)		8385	D	$0.00	0	I	See Footnote (7)
Common Stock	4/26/2021		J(9)		2226	A	$0.00	2226	D
Common Stock								862444	I	See Footnote (10)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("VVC VI") to its partners pursuant to a Rule 10b5-1 trading plan.
(2)	Shares held by VVC VI. Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
(3)	Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC VI.
(4)	Shares held by VV VI GP. VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
(5)	Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its partners.
(6)	Represents a change in the form of ownership of VV VI GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP.
(7)	Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
(8)	Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP-GP, to its members.
(9)	Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP-GP.
(10)	Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. The Reporting Person is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Woiwode Thomas C/O ALIGOS THERAPEUTICS, INC. ONE CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO, CA 94080	X

Signatures
/s/ Robin L. Praeger, Attorney-in-fact for Thomas Woiwode		4/28/2021
**Signature of Reporting Person		Date